What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.

What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.

Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several year...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Testa, L, Bhindi, R, Van Gaal, W, Latini, R, Pizzocri, S, Lanotte, S, Biondi Zoccai, G, Valgimigli, M, Laudisa, M, Brambilla, N, Banning, A, Bedogni, F
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	2010

Eitemau Tebyg

Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis.
gan: Testa, L, et al.
Cyhoeddwyd: (2010)

Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents
gan: L. Testa, et al.
Cyhoeddwyd: (2010-01-01)

Use of prasugrel in patients with clopidogrel hypersensitivity
gan: Aparna Joshi, et al.
Cyhoeddwyd: (2022-01-01)

Interaction between statins and clopidogrel: is there anything clinically relevant?
gan: Bhindi, R, et al.
Cyhoeddwyd: (2008)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
gan: Satoshi Niijima, et al.
Cyhoeddwyd: (2018-03-01)

Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition.
gan: Testa, L, et al.
Cyhoeddwyd: (2009)

Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms
gan: Dongwhane Lee, et al.
Cyhoeddwyd: (2018-09-01)

Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders
gan: Philip M Bath, et al.
Cyhoeddwyd: (2018-07-01)

Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis
gan: Gerhard Selhorst, et al.
Cyhoeddwyd: (2019-04-01)

Repeat thrombolysis or conservative therapy vs. rescue percutaneous coronary intervention for failed thrombolysis: systematic review and meta-analysis.
gan: Testa, L, et al.
Cyhoeddwyd: (2008)

Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
gan: Jan Kiebist, et al.
Cyhoeddwyd: (2021-09-01)

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
gan: Jim McLenachan, et al.
Cyhoeddwyd: (2019-05-01)

In silico Investigation on Clopidogrel, Prasugrel and Ticagrelor as Potential Mono Antiplatelet Therapy for Acute Coronary Syndrome
gan: Muhammad Naufal Hibatullah, et al.
Cyhoeddwyd: (2024-11-01)

Effect of CYP2C19 status on platelet reactivity in Taiwanese acute coronary syndrome patients switching to prasugrel from clopidogrel: Switch Study
gan: Feng-Yu Kuo, et al.
Cyhoeddwyd: (2022-09-01)

Prasugrel
gan: Gianluca Airoldi, et al.
Cyhoeddwyd: (2013-04-01)

Correction: Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
Cyhoeddwyd: (2019-07-01)

Stent Thrombosis Patients with Hyporesponsiveness to Clopidogrel, Prasugrel, and Ticagrelor: A Case Series Using Short Thromboelastography
gan: Bartosz Olechowski, et al.
Cyhoeddwyd: (2016-01-01)

Impact of immature platelet fraction on platelet reactivity during prasugrel maintenance treatment
gan: Monica Verdoia, et al.
Cyhoeddwyd: (2019-10-01)

Low-dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms: Follow-up of over 6 Months
gan: Dongwhane Lee, et al.
Cyhoeddwyd: (2019-03-01)

Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients.
gan: Testa, L, et al.
Cyhoeddwyd: (2008)

Clopidogrel, ticagrelor, prasugrel or an alternation of two P2Y12 in patients with acute myocardial infarction with cardiogenic shock
gan: Vojko Kanic, et al.
Cyhoeddwyd: (2024-01-01)

Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention
gan: Yuri Kim, et al.
Cyhoeddwyd: (2023-01-01)

Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention.
gan: Yuri Kim, et al.
Cyhoeddwyd: (2023-01-01)

Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low‐Dose Prasugrel or Clopidogrel
gan: Gabriele Crimi, et al.
Cyhoeddwyd: (2019-01-01)

Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication
gan: Constance C. F. M. J. Baaten, et al.
Cyhoeddwyd: (2015-09-01)

Prognostic significance of small troponin I rise after a successful elective percutaneous coronary intervention of a native artery.
gan: Testa, L, et al.
Cyhoeddwyd: (2009)

Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel
gan: Shokoufeh Hajsadeghi, et al.
Cyhoeddwyd: (2016-01-01)

Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel
gan: Shokoufeh Hajsadeghi, et al.
Cyhoeddwyd: (2016-08-01)

The effect of doubling the dose of clopidogrel on platelet aggregation in patients with clopidogrel resistance
gan: John I. Louca, et al.
Cyhoeddwyd: (2014-09-01)

NICHE OF PRASUGREL AMONG OTHER PLATELET P2Y12-RECEPTOR INHIBITORS
gan: P. S. LAGUTA, et al.
Cyhoeddwyd: (2017-12-01)

Legacy of blood: does prasugrel inhibit megakaryocytes and do juvenile platelets inherit this inhibition?
gan: Carlos G. Santos-Gallego
Cyhoeddwyd: (2015-09-01)

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
gan: Lulu Dai, et al.
Cyhoeddwyd: (2022-06-01)

The hurdles of translating a single-center observation into practice.
gan: Testa, L, et al.
Cyhoeddwyd: (2008)

Digitalis: a dangerous drug in atrial fibrillation?
gan: Testa, L, et al.
Cyhoeddwyd: (2008)

Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry
gan: Goldstein P, et al.
Cyhoeddwyd: (2016-04-01)

Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis
gan: Zhe Wang, et al.
Cyhoeddwyd: (2020-03-01)

The effect of concurrent clopidogrel and omeprazole administration on clopidogrel metabolism and platelet function in healthy cats
gan: Christina Plante, et al.
Cyhoeddwyd: (2024-11-01)

Sepsis favors high-on-clopidogrel platelet reactivity
gan: Karolina Akinosoglou, et al.
Cyhoeddwyd: (2018-01-01)

Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders
gan: Wiktor Kuliczkowski, et al.
Cyhoeddwyd: (2021-01-01)

PRASUGREL: FREQUENTLY ASKED QUESTIONS FROM PRACTITIONERS
gan: O. O. Shakhmatova, et al.
Cyhoeddwyd: (2019-06-01)